JAN 0 5 2007 B

PTO/SB/08A/B (09-06)
Approved for use through 03/31/2007. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE respond to a collection of information wiless it contains a yell OMB control number.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 1 of 3

Complete If Known					
Application Number	09/284,683				
Filing Date	June 24, 1999				
First Named Inventor	Gregor CEVC				
Art Unit	1615				
Examiner Name	G. S. Kishore				
Attorney Docket Number	2001377.123-US1				

	U.S. PATENT DOCUMENTS					
Examine Initials	r Cite	Document Number Number-Kind Code (# known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	
	JAA	US-4,666,747	05-19-1987	Quinn et al.	1 90.007 40.00	
\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\	AB					
\vdash	AC	US-4,731,210	03-15-1988			
\vdash		US-4,746,509	05-24-1988			
$\vdash \vdash$	AD	US-4,783,450	11-08-1988	Fawzi et al.		
├	AE	US-5,104,661	04-14-1992			
├	AF	US-5,145,684	09-08-1992			
	AG	US-5,154,930	10-13-1992			
┝╌┼	AH	US-5,498,418	03-12-1996			
┝╌┼	Al	US-5,510,118	04-23-1996			
<i>\</i>	AJ.	US-5,552,160	09-03-1996			
 -	AK	US-5,648,095	07-15-1997	Illum et al.	· · · · · · · · · · · · · · · · · · ·	
$\vdash \vdash$	AL.	US-5,654,337	08-05-1997	Roentsch et al.		
\vdash	AM	US-5,716,638	02-10-1998			
\vdash	AN	US-5,763,422	06-09-1998	Lichtenberger et al. Grasela et al.	<u> </u>	
	AO	US-5,837,289	11-17-1998			
I —	AP	US-5,858,330	01-12-1999	Boltri et al.	 	
├ -		US-5,874,422	02-23-1999	Krause et al.		
⊢	AR	US-5,985,860	11-16-1999	Торро		
├	AS	US-6,028,066	02-22-2000	Unger		
⊢	AT	US-6,045,827	04-04-2000			
Н	AU	US-6,069,172	05-30-2000			
├-	AV	US-6,083,996	07-04-2000			
├	AW	US-6,193,996	02-27-2001	Effing et al.		
Н—	AX	US-6,200,598	03-13-2001	Needham		
Н—	AY	US-6,214,386	04-10-2001	Santus et al.		
Н	AZ	US-6,248,353	06-19-2001	Singh		
H	AA1	US-20010012849-A1	08-09-2001			
H	AB1	US-6,294,192	09-25-2001	Patel et al.	·	
 	AC1	US-6,303,141	10-16-2001	Fischer et al.		
Н—	AD1	US-20020003179-A1	01-10-2002			
H	AE1		01-31-2002			
Н	AF1	US-20020037877-A1	03-28-2002			
Н	AG1	US-20020048596-A1	04-25-2002			
\vdash	AH1	US-6,387,383	05-14-2002		ļ	
⊢+	Al1	US-20020106345-A1	08-08-2002		ļ	
├	AJ1	US-20020119188-A1	08-29-2002			
⊢—	AK1	US-6,448,296-A1	09-10-2002			
\vdash	AL1	US-6,451,339-A1	09-17-2002			
	AM1	US-20020147238-A1	10-10-2002			
Н-	AN1	US-6,562,370-A1	05-13-2003			
 	A01	US-6,582,724-A1	06-24-2003			
 	AP1	US-6,586,000-A1	07-01-2003	Luo et al.		
	AQ1	US-6,645,520-A1	11-11-2003			
├	AR1	US-6,645,529-A1	11-11-2003		<u> </u>	
	_AS1	US-6,726,598	04-27-2004	Jarvis et al.	L	

Examiner Signature	Krohn	Date Considered	21	26/07	
6005885			-		

PTO/SB/08A/B (09-06)
Approved for use through 03/31/2007. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Complete If Known Substitute for form 1449/PTO Application Number 09/284,683 **INFORMATION DISCLOSURE** Filing Date June 24, 1999 STATEMENT BY APPLICANT **Gregor CEVC** First Named Inventor Art Unit 1615 (Use as many sheets as necessary) Examiner Name G. S. Kishore 3 2001377.123-US1 Attorney Docket Number

AT1	US-6,835,392-A1	12-28-2004	Hsu et al.
AU1	US-20030099694	5-29-2003	Cevc et al.
AV1	US-20050123897	6-9-2005	Cevc et al.

			FOREI	GN PATENT	DOCUMENTS		
Exam	inor	Cite	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Pages, Columns, Line		П
Initials		No.	Country Code -Number-Kind Code (if known)		Applicant of Cited Document	Where Relevant Passages or Relevant Figures Appear	
m		ВА	English Language Abstract of WO-92/22292	12-23-1992	SCHWARZ PHARMA AG		1
		ВВ	EP-0 355 095	08-04-1993	THE LIPOSOME COMPANY, INC.		
		ВС	English Language Abstract of WO-94/26257	11-24-1994	LTS LOHMANN THERAPIE- SYSTEME GMBH & CO.		7
		BD	English Language Abstract of WO-96/29999	10-03-1996	HEXAL AG		1
	Γ	BE	EP-0 382 716	01-28-1998	WARNER-LAMBERT CO.		
	L	BF	WO-98/07414	02-26-1998	RESEARCH TRIANGLE PHARMACEUTICALS LTD.		
			WO-98/30215	07-16-1998			
	Ŀ	ВН	WO-99/22703		LURIDENT LTD.		
		ВІ	WO-00/00597	01-06-2000	THE UNIVERSITY OF MANITOBA		
		BJ	WO-00/13684	03-16-2000	LOMA LINDA UNIVERSITY MEDICAL CENTER		
		ВК	EP-0 995 435	04-26-2000	SENJU PHARMACEUTICAL CO., LTD.	;	
		BL	WO-00/25822	05-11-2000	John C. Grasela, et al.		П
		ВМ	WO-00/44350	08-03-2000	IDEA AG		
	Ц	BN	WO-00/50007	08-31-2000	LIPOCINE, INC.		
	\Box	во	WO-01/12155		LIPOCINE, INC.	•	
	\Box	BP	WO-02/07767	01-31-2002	ALCON UNIVERSAL, LTD.		
			WO-02/11683	02-14-2002	DOW PHARMACEUTICAL SCIENCES		
	<u>~</u>	BR	EP-1 031 346	05-02-2002		·	
			NON PATE	IT LITERATI	JRE DOCUMENTS		
Exam Initials		Cite No.	include name of the author, title of the symposium, catalog, etc.), date,	page(s), volume	ppropriate), title of the item (book, ma issue number(s), publisher, city and/ iblished.	gazine, journal, serial, or country where	T²
h	<u> </u>	CA _.	Calpena, A. et al., "Influence of the Formulation on the In Vitro Transdermal Penetration of Sodium Diclofenac," ArzneimForsch./Drug-Res, 49(II), 1012-1017 (1999).				
1		СВ	Carafa, M. et al. "Lidocaine-loaded Non-ionic Surfactant Vesicles: Characterization and In Vitro Permeation Studies," International Journal of Pharmaceutics 231:21-32. (2002).				
		CC	Cevc, G. " Drug Delivery Across				
b		CD	Cevc, G. et al." Newly, Highly Efficient Formulation of Diclofenac for the Topical, Transdermal Administration in Ultradeformable Drug Carriers, Transfersomes," Biochimica et Biophysica Acta 1514 (2001) 191-205.				

Examiner Signature	Kulu	,	Date Considered	2/26	07.
6005885					

PTO/SB/08A/B (09-06)
Approved for use through 03/31/2007. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to asspond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				Complete If Known		
	•			Application Number	09/284,683	
11	IFORMATIC)N DI	SCLOSURE	Filing Date	June 24, 1999	
S	STATEMENT BY APPLICANT (Use as many sheets as necessary)			First Named Inventor	Gregor CEVC	
				Art Unit	1615	
				Examiner Name	G. S. Kishore	
Sheet	3	of	3	Attorney Docket Number	2001377.123-US1	

ly	CE	Cevc, G. et al., "Transfersomes-mediated transepidermal delivery improves the regio- specificity and biological actibity of corticosteroids in vivo," Journal of Controlled Release 45 (1997) 211-226.	
	CF	Friedrich, I. et al., "Physicochemical Characterization of a Reverse Micellar Solution after Loading with Different Drugs," Pharmazie 55 (2000) 10, 755-758.	
	CG	Gesztes, A. et al., "Topical Anesthesia of the Skin by Liposome-Encasulated Tetracaine, Anesth Analg 1988 67 1079-1081.	П
	СН	Schramlova, J. et al., "The Effect of an Antiphlogisitc Incorporated in Liposomes on Expérimentally Induced Inflammation," Fola Biológica (Praha) 43, 195-199 (1997).	П
	CI	Stoye, I. et al., "Transformation of a Liposomal Dispersion Containing Ibuproen Lysinate and Phospholipids into Mixed Micelles - Physico-chemical Characterization and Influence on Drug Permeation through Excised Human Stratum Comeum, European Journal of Pharmaceuticals and Biopharmaceuticals 46 (1998) 191-200.	
~~	CJ	Valenta, C. et al., "Evalutation of Novel Soya-lecithin Formulations for Dermal use containing Ketoprofen as a Model Drug," Journal of Controlled Release 63 (2000) 165-173.	

²Applicant is to place a check mark here if English language Translation is attached.